ABSTRACT
The spontaneous reporting system for adverse drug reactions(ADRs), through which information is collected on patients who experience ADRs, can lead to hypotheses on causal relationships between drugs and ADRs; however, lack of information on patient characteristics or patients who have not experienced ADRs makes quantitative, relative comparison of risks difficult. From the viewpoint of adapting pharmacoepidemiology to supplement spontaneous reporting of ADRs, RAD-AR Council Japan(RCJ) has been promoting development of a database assembling drug use-results surveillance(DURS) data under the re-examination system for secondary use. RCJ received observational DURS data on antihypertensive drug users from pharmaceutical companies and integrated to develop a database of over 100,000 patients and 19 antihypertensives in 2003. RCJ maintains the database, expanding it to 143,509 patients and 21 antihypertensives in 2007, and also developed a database of antihyperlipidemics with approximately 34,000 patients in 2011. Researchers study these databases through an application and protocol review process stipulated by RCJ, and their results have been presented at conferences and published in articles. This report summarizes DURS data collection and its underpinning regulated systems in terms of data assembly and database maintenance at RCJ. The report also introduces the example for constructing the antihyperlipidemics DURS database and summarizes its patient characteristics. The database is characterized by ADR information and treatment-related laboratory values in addition to patient backgrounds and drug use information. However, it is too small to study rare ADRs and has limited longitudinal observational data. Therefore, RCJ worked to expand the antihypertensives DURS database in 2012 by adding data that include long-term surveillance results. (Jpn J Pharmacoepidemiol 2012; 17(2): 87-97)
ABSTRACT
OBJECTIVE: To analyze the status quo and developing trend of the use of antihyperlipidemics drugs in Chongqing so as to provide information for the research,production,marketing and clinical application of these drugs.METHODS: The consumption sum,DDDs and the defined daily cost(DDC) of Antihyperlipidemics in 18 hospitals in Chongqing city from 2004 to 2006 were analyzed statistically.RESULTS: Both the DDDs and the consumption sum of the antihyperlipidemics showed uptrend over the 3 years,with statins dominating the first place over the 3 consecutive years,making up 48.37%,47.74%,and 61.79% respectively,followed by Chinese patent medicines and fibrates.Xuezhikang and simvastatin ranked among the first two places in terms of DDDs.CONCLUSION: Statins and Chinese patent medicines occupied a predominant role among all the antihyperlipidemic drugs in Chongqing,and their use had a bright prospect.
ABSTRACT
OBJECTIVE:To evaluate the status and tendency of the application of antihyperlipidemics drugs in Chongqing area. METHODS: The use of antihyperlipidemics drugs in 28 hospitals of Chongqing from 2004 to 2007 was analyzed statistically in respect of the consumption sum, DDDs and DDC. RESULTS: The mean annual incremental ratio of the consumption sum of antihyperlipidemics drugs reached over 33.80%. Simvastatin has been dominated the first place over the 4 years in terms of consumption sum and DDDs; the consumption sum of atorvastatin has been on the rise but that of Gemfibrozil decreased year on year with mean annual decrement of 60%. CONCLUSION: Statins assumed a dominant position among all the antihyperlipidemics drugs used in Chongqing area and its use has great potential.
ABSTRACT
OBJECTIVE:To eualuate the situation and the tondency of antihyperlipidemics used in Guangdong Province.METHODS:The sales volume,DDDs and daily expense of antihyperlipidemics in Guangdong Province from2000to2003were investigated and analyzed.RESULTS:The sales volumes of cardiovascular agents from2000to2003had been increasing.The proportion of antihyperlipidemics to cardiovascular agents in respect of sales volume assumed a decreasing tendency from2001.Simvastatin dominated over all other drugs in respect of sales volume and DDDs.CONCLUSION:HMG-CoA reductase in-hibitor and natural drugs dominate in the antihyperlipidemics market of Guangdong Province.